Articles from AdipoPharma

STRASBOURG, France, Oct. 27, 2026 (GLOBE NEWSWIRE) -- AdipoPharma, a clinical-stage biotechnology company developing therapies that target adipocyte dysfunction to treat metabolic diseases, today announced the initiation of Phase 1B of its ongoing Phase 1 clinical trial evaluating PATAS. The first participants have been enrolled and dosed in the multiple ascending dose portion of the study, which is being conducted in patients with Type 2 diabetes.

This novel whole-body insulin-sensitizing approach is designed to address insulin resistance independent of weight loss

CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the U.S. and Belgium, was recognized at the American Diabetes Association’s 85th Annual Meeting this week in Chicago for its novel and promising insulin-sensitizing peptide PATAS, set to treat Type 2 diabetes and correct its root cause.

Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes